Drugs / rHIgM22
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02398461 | Apr 2015 → Sep 2017 | multiple sclerosis | Acorda Therapeutics | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01803867 Comparator | Mar 2013 → Oct 2014 | multiple sclerosis | Acorda Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rHIgM22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02398461 ↗ |
| Action | Restore | “Recombinant human immunoglobulin M22 (rHIgM22) has promoted remyelination in animal models and was well tolerated in people with clinically stable multiple sclerosis.” PMID 35496758 ↗ Apr 2022 |
| Modality | Protein / enzyme biologic | “Recombinant Human Immunoglobulin M (rHIgM22)” NCT01803867 ↗ |
| Route | Intravenous | “Administered via IV infusion” NCT01803867 ↗ |